세계의 유전체 암 패널 및 프로파일링 시장 : 암 유형별, 용도별, 조직별, 유전자 유형별, 잠재적 시장 스크리닝, 규모 - 주요 컨설턴트 가이드 첨부(2026-2030년)

Report Overview:

Cancer Gene Panels and Genomic Profiling are quickly changing the diagnosis and treatment of cancers. And now Artificial Intelligence is opening new doors. The market is moving out of a specialized niche and going mainstream as Oncologists begin routinely using information on the hundreds of genes related to cancer. The market is exploding in two distinct segments. Find out how this new way of understanding cancer will change cancer diagnostics forever.

Comprehensive panels, genomic profiling, high risk breast cancer panels. Learn all about how players are jockeying for position in a market that is being created from scratch. And some players are pulling way out in front and expanding globally. It is a dynamic market situation with enormous opportunity where the right diagnostic with the right support can command premium pricing. And the science is developing at the same time creating new opportunities with regularity. And the cost of sequencing continues to fall.

The report includes detailed breakouts for 18 Countries and 4 Regions. A detailed breakout for any country in the world is available to purchasers of the report.

Table of Contents

1. Market Guides

• 1.1. Cancer Panel Market - Strategic Situation Analysis
• 1.2. Large Comprehensive Cancer Panel Market - Situation Analysis
• 1.3. Guide for Executives, Marketing, Sales and Business Development Staff
• 1.4. Guide for Management Consultants and Investment Advisors
• 1.5. Impact of Artificial Intelligence on Cancer Profiling Market

2. Introduction and Market Definition

• 2.1. What are Cancer Gene Panels and Profiling?
• 2.2. The Sequencing Revolution
• 2.3. Market Definition
  • 2.3.1. Revenue Market Size
• 2.4. Methodology
  • 2.4.1. Methodology
  • 2.4.2. Sources
  • 2.4.3. Authors
• 2.5. Perspective: Healthcare Spending
  • 2.5.1. Global Healthcare Spending
  • 2.5.2. Spending on Healthcare and Pharmaceuticals
  • 2.5.3. Spending on Diagnostics
  • 2.5.4. Important Role of Insurance for Medical Services

3. Market Overview

• 3.1. Players in a Dynamic Market
  • 3.1.1. Academic Research Lab
  • 3.1.2. Diagnostic Test Developer
  • 3.1.3. Instrumentation Supplier
  • 3.1.4. Chemical/Reagent Supplier
  • 3.1.5. Pathology Supplier
  • 3.1.6. Independent Clinical Laboratory
  • 3.1.7. Public National/regional Laboratory
  • 3.1.8. Hospital Laboratory
  • 3.1.9. Physicians Office Lab (POLS)
  • 3.1.10. Audit Body
  • 3.1.11. Certification Body
• 3.2. Oncogenomics
  • 3.2.1. Carcinogenesis
  • 3.2.2. Chromosomes, Genes and Epigenetics
    • 3.2.2.1. Chromosomes
    • 3.2.2.2. Genes
    • 3.2.2.3. Epigenetics
  • 3.2.3. Cancer Genes
  • 3.2.4. Germline vs Somatic
  • 3.2.5. Gene Panels, Single Gene Assays and Multiplexing
  • 3.2.6. Genomic Profiling
  • 3.2.7. The Comprehensive Assay
  • 3.2.8. Changing Clinical Role
  • 3.2.9. The Cancer Screening Market Opportunity
• 3.3. Cancer Management vs. Diagnosis
  • 3.3.1. The Role of Risk Assessment
  • 3.3.2. Diagnosis
  • 3.3.3. Managing
  • 3.3.4. Monitoring
• 3.4. Phases of Adoption - Looking into The Future
• 3.5. Structure of Industry Plays a Part
  • 3.5.1. Hospital Testing Share
  • 3.5.2. Economies of Scale
    • 3.5.2.1. Hospital vs. Central Lab
  • 3.5.3. Physician Office Lab's
  • 3.5.4. Physician's and POCT
• 3.6. Currently Available Large Comprehensive Assays
• 3.7. Pricing Profiling vs. Whole Exome (or Genome) Sequencing
  • 3.7.1. Medicare Profile Pricing
  • 3.7.2. Whole Exome Sequencing

4. Market Trends

• 4.1. Factors Driving Growth
  • 4.1.1. Level of Care
  • 4.1.2. Companion Dx
  • 4.1.3. Immuno-oncology
  • 4.1.4. Liability
  • 4.1.5. The Aging Effect
• 4.2. Factors Limiting Growth
  • 4.2.1. State of knowledge
  • 4.2.2. Genetic Blizzard
  • 4.2.3. Protocol Resistance
  • 4.2.4. Regulation and coverage
• 4.3. Instrumentation and Automation
  • 4.3.1. Instruments Key to Market Share
  • 4.3.2. Bioinformatics Plays a Role
• 4.4. Diagnostic Technology Development
  • 4.4.1. Next Generation Sequencing Fuels a Revolution
  • 4.4.2. Single Cell Genomics Changes the Picture
  • 4.4.3. Pharmacogenomics Blurs Diagnosis and Treatment
  • 4.4.4. CGES Testing, A Brave New World
  • 4.4.5. Biochips/Giant magneto resistance based assay

5. Cancer Panels & Profiles Recent Developments

• 5.1. Recent Developments - Importance and How to Use This Section
  • 5.1.1. Importance of These Developments
  • 5.1.2. How to Use This Section
• 5.2. Labcorp Completes Acquisition of Oncology Testing Assets
• 5.3. QIAGEN Acquires Genoox
• 5.4. Illumina Genomic Profiling Test Receives Japan Approval
• 5.5. Otsuko Launches the First-in-Japan Comprehensive Genomic Profiling Assay
• 5.6. Foundation Medicine, Fulgent Genetics to Launch Germline Testing
• 5.7. Advanced Genomics APAC, 3BIGS Partner on Cancer Testing
• 5.8. Lucence Assay Gets Coverage for Advanced Solid Tumors
• 5.9. Foundation Medicine, AnHeart Therapeutics to Develop CDx for NSCLC Therapy
• 5.10. Roche CGP Assay Shows Concordance With Other NGS-Based Assays
• 5.11. Precede Biosciences Emerges From Stealth With $57M
• 5.12. Geneseeq Nabs CE Marks for Cancer Test Kits
• 5.13. Realm IDx Profiling Test Gets National Health Coverage in Japan
• 5.14. Foundation Medicine, Merck KGaA to Collaborate on Companion Diagnostics
• 5.15. Guardant Health Secures Coverage for Liquid Biopsy Profiling Test
• 5.16. Myriad Genetics, Intermountain Precision Genomics Obtain NY Certification for Tumor Profiling
• 5.17. Cota, Genomic Testing Coop Ink Oncology Partnership
• 5.18. Euformatics, ViennaLab, Oncompass Win Liquid Biopsy Development Contract
• 5.19. Prenetics' Cancer Profiling Test Receives FDA Clearance
• 5.20. Genetic Profiling May Identify Patients Who Do Not Need Radiation Therapy
• 5.21. Thermo Fisher Introduces Homologous Score for Cancer Profiling
• 5.22. Genomic Test IDs Cancer Cells Early
• 5.23. Caris Life Sciences to Offer Molecular Profiling Services
• 5.24. Geneseeq to Build Lab for Cancer Profiling in Brazil
• 5.25. Genetron Health Adds New Assays to Pipeline
• 5.26. Illumina Obtains CE-IVD Marking for TSO Comprehensive Assay
• 5.27. Guardant Health Receives Medicare Coverage for Guardant360 TissueNext(TM) Test
• 5.28. Cancer Screening Launch Approaches, Guardant Health Plans New Comprehensive Assay
• 5.29. Thermo Fisher, Oncocyte Ink Deal for Cancer IVDs
• 5.30. Local Cancer Genomic Profiling Options Grow, Though Central Labs Will Likely Keep Major Role
• 5.31. Labcorp, CCORN Partner for Precision Oncology
• 5.32. Dante Labs Acquires Cambridge Cancer Genomics
• 5.33. Celemics, Strand Partner on Integrated Platform for NGS Analysis
• 5.34. Myriad Genetics Recalibrates Breast Cancer Panel for All Ancestries
• 5.35. Burning Rock Revenues Rise
• 5.36. Caris Life Sciences to Expand Liquid Biopsy Testing
• 5.37. OncoDiag Announces Multiplex Test for Bladder Cancer Recurrence
• 5.38. Intermountain and Myriad Combine Test Offering
• 5.39. Illumina, Geneseeq to Offer Cancer Testing Kits in China
• 5.40. Exact Sciences to Offer End-to-End Cancer Testing
• 5.41. Guardant Health Turns to Tumor Tissue Sequencing
• 5.42. Tempus Inks Oncology Testing Collaboration With Bayer
• 5.43. Biocartis Collaborating With GeneproDx, Endpoint Health on Tests for Idylla Platform
• 5.44. Wales to Routinely Screen Cancer Patients With Yourgene Elucigene Test
• 5.45. Metastatic Cancer Markers Identified in Clinical WGS Study
• 5.46. Stitch Bio Bets on CRISPR Tech
• 5.47. Bayer, LifeLabs Launch Free NTRK Genetic Testing Program
• 5.48. Foundation Medicine Liquid Biopsy Gets FDA Approval for Multiple Companion Dx
• 5.49. Progress, Challenges in Liquid Biopsy Reimbursement
• 5.50. Israeli Startup Curesponse Raises $6M
• 5.51. Invitae, ArcherDX Merge to Advance Precision Oncology Offerings
• 5.52. MD Anderson Precision Oncology Decision Support to Use Philips' Informatics Solution
• 5.53. NeoGenomics, Lilly Oncology Partner for Thyroid Cancer Testing Program
• 5.54. Germline Results Guides Precision Therapy in Advanced Cancer
• 5.55. FDA Clears Cancer Genomic Profiling Kit From Personal Genome Diagnostics
• 5.56. ArcherDX, Premier Collaborate to Evaluate Genomic Sequencing Assay for Cancers
• 5.57. Labs Reporting Cancer Risk Mutations from Tumor Testing
• 5.58. Users Begin Integrating Genomics Data for Clinical Decision Support
• 5.59. Fujitsu Improves Efficiency in Cancer Genomic Medicine

6. Profiles of Key Players

• 6.1. 10x Genomics, Inc.
• 6.2. Abbott Laboratories
• 6.3. AccuraGen Inc.
• 6.4. Adaptive Biotechnologies
• 6.5. Admera Health, LLC
• 6.6. Aethlon Medical
• 6.7. Agilent
• 6.8. Amoy Diagnostics Co., Ltd.
• 6.9. Anchor Dx
• 6.10. ANGLE plc
• 6.11. ARUP Laboratories
• 6.12. AVIVA Systems Biology
• 6.13. Baylor Miraca Genetics Laboratories
• 6.14. Beckman Coulter Diagnostics (Danaher)
• 6.15. Becton, Dickinson and Company
• 6.16. BGI Genomics Co. Ltd
• 6.17. Bioarray Genetics
• 6.18. Biocartis
• 6.19. Biocept, Inc.
• 6.20. Biodesix Inc.
• 6.21. BioFluidica
• 6.22. BioGenex
• 6.23. BioIVT
• 6.24. Biolidics Ltd
• 6.25. bioMerieux Diagnostics
• 6.26. Bioneer Corporation
• 6.27. Bio-Rad Laboratories, Inc
• 6.28. Bio-Reference Laboratories
• 6.29. Bio-Techne
• 6.30. Bioview
• 6.31. Bristol-Myers Squibb
• 6.32. Burning Rock
• 6.33. C2i Genomics
• 6.34. Cardiff Oncology
• 6.35. Caris Molecular Diagnostics
• 6.36. Castle Biosciences, Inc.
• 6.37. Celemics
• 6.38. CellMax Life
• 6.39. Cepheid (Danaher)
• 6.40. Charles River Laboratories
• 6.41. Circulogene
• 6.42. Clearbridge Biomedics
• 6.43. Clinical Genomics
• 6.44. Cytolumina Technologies Corp.
• 6.45. Datar Cancer Genetics Limited
• 6.46. Diagnologix LLC
• 6.47. Diasorin S.p.A.
• 6.48. Element Biosciences
• 6.49. Enzo Biochem
• 6.50. Epic Sciences
• 6.51. Epigenomics AG
• 6.52. Eurofins Scientific
• 6.53. Exact Sciences
• 6.54. Fabric Genomics
• 6.55. Fluxion Biosciences (Cell Microsystems)
• 6.56. Freenome
• 6.57. FUJIFILM Wako Diagnostics
• 6.58. Fujirebio
• 6.59. GeneDx Holdings
• 6.60. GeneFirst Ltd.
• 6.61. Genetic Technologies Ltd.
• 6.62. Genetron Holdings
• 6.63. GenomOncology
• 6.64. GILUPI Nanomedizin
• 6.65. Guardant Health
• 6.66. HansaBiomed
• 6.67. HTG Molecular Diagnostics
• 6.68. iCellate
• 6.69. ICON PLC
• 6.70. Illumina
• 6.71. Incell Dx
• 6.72. Inivata
• 6.73. Invitae Corporation
• 6.74. Invivogen
• 6.75. Invivoscribe
• 6.76. J&J Innovative Medicine
• 6.77. KEW
• 6.78. Lucence Health
• 6.79. Lunglife AI Inc
• 6.80. MDNA Life SCIENCES, Inc.
• 6.81. MDx Health
• 6.82. Menarini Silicon Biosystems
• 6.83. Mesa Laboratories, Inc.
• 6.84. Millipore Sigma
• 6.85. Miltenyi Biotec
• 6.86. miR Scientific
• 6.87. Myriad Genetics
• 6.88. Nanostring
• 6.89. NantHealth, Inc.
• 6.90. Natera
• 6.91. NeoGenomics
• 6.92. NGeneBio
• 6.93. Novogene
• 6.94. Oncimmune
• 6.95. Oncocyte
• 6.96. OncoDNA
• 6.97. OraLiva
• 6.98. Oxford Nanopore Technologies
• 6.99. Panagene
• 6.100. Personalis
• 6.101. Perthera
• 6.102. PGDx (Labcorp)
• 6.103. Precipio
• 6.104. PrecisionMed
• 6.105. Predictive Oncology
• 6.106. Prenetics
• 6.107. Promega
• 6.108. Qiagen
• 6.109. QuidelOrtho
• 6.110. Rarecells SAS
• 6.111. RareCyte
• 6.112. Revvity
• 6.113. Roche Diagnostics
• 6.114. Screencell
• 6.115. Sherlock Biosciences
• 6.116. Siemens Healthineers
• 6.117. simfo GmbH
• 6.118. Singlera Genomics Inc.
• 6.119. Singular Genomics
• 6.120. Singulomics
• 6.121. SkylineDx
• 6.122. Standard BioTools
• 6.123. Stilla Technologies
• 6.124. Sysmex Inostics
• 6.125. Tempus Labs, Inc.
• 6.126. Thermo Fisher Scientific
• 6.127. Todos Medical
• 6.128. Ultima Genomics
• 6.129. Variantyx
• 6.130. Vela Diagnostics
• 6.131. Veracyte
• 6.132. VolitionRX
• 6.133. Vortex Biosciences

7. The Global Market for Cancer Gene Panels and Profiles

• 7.1. Global Market Overview by Country
  • 7.1.1. Table - Global Market by Country
  • 7.1.2. Chart - Global Market by Country
• 7.2. Global Market by Cancer Type - Overview
  • 7.2.1. Table - Global Market by Cancer Type
  • 7.2.2. Chart - Global Market by Cancer Type - Base/Final Year Comparison
  • 7.2.3. Chart - Global Market by Cancer Type - Base Year
  • 7.2.4. Chart - Global Market by Cancer Type - Final Year
  • 7.2.5. Chart - Global Market by Cancer Type - Share by Year
  • 7.2.6. Chart - Global Market by Cancer Type - Segment Growth
• 7.3. Global Market by Application - Overview
  • 7.3.1. Table - Global Market by Application
  • 7.3.2. Chart - Global Market by Application - Base/Final Year Comparison
  • 7.3.3. Chart - Global Market by Application - Base Year
  • 7.3.4. Chart - Global Market by Application - Final Year
  • 7.3.5. Chart - Global Market by Application - Share by Year
  • 7.3.6. Chart - Global Market by Application - Segment Growth
• 7.4. Global Market by Tissue - Overview
  • 7.4.1. Table - Global Market by Tissue
  • 7.4.2. Chart - Global Market by Tissue - Base/Final Year Comparison
  • 7.4.3. Chart - Global Market by Tissue - Base Year
  • 7.4.4. Chart - Global Market by Tissue - Final Year
  • 7.4.5. Chart - Global Market by Tissue - Share by Year
  • 7.4.6. Chart - Global Market by Tissue - Segment Growth
• 7.5. Global Market Germline & Somatic - Overview
  • 7.5.1. Table - Global Market Germline & Somatic
  • 7.5.2. Chart - Global Market Germline & Somatic - Base/Final Year Comparison
  • 7.5.3. Chart - Global Market Germline & Somatic - Base Year
  • 7.5.4. Chart - Global Market Germline & Somatic - Final Year
  • 7.5.5. Chart - Global Market Germline & Somatic - Share by Year
  • 7.5.6. Chart - Global Market Germline & Somatic - Segment Growth

8. Global Cancer Gene Panels & Profiles Markets - By Type of Cancer

• 8.1. Comprehensive Panels & Profiles
  • 8.1.1. Table Comprehensive Testing - by Country
  • 8.1.2. Chart - Comprehensive Testing Growth
• 8.2. Breast Cancer Gene Testing
  • 8.2.1. Table Breast Cancer Gene Testing - by Country
  • 8.2.2. Chart - Breast Cancer Testing Growth
• 8.3. Colorectal Cancer Gene Testing
  • 8.3.1. Table Colorectal Cancer Gene Testing - by Country
  • 8.3.2. Chart - Colorectal Cancer Gene Testing Growth
• 8.4. Gynecological Cancer Gene Testing
  • 8.4.1. Table Gynecological Cancer Gene Testing - by Country
  • 8.4.2. Chart - Gynecological Cancer Gene Testing Growth
• 8.5. Blood Cancer Gene Testing
  • 8.5.1. Table Blood Cancer Gene Testing - by Country
  • 8.5.2. Chart - Blood Cancer Gene Testing Growth
• 8.6. Prostate Cancer Gene Testing
  • 8.6.1. Table Prostate Cancer Gene Testing - by Country
  • 8.6.2. Chart - Prostate Cancer Testing Growth
• 8.7. Lung Cancer Gene Testing
  • 8.7.1. Table Lung Cancer Gene Testing - by Country
  • 8.7.2. Chart - Lung Cancer Gene Testing Growth
• 8.8. Other Cancer Gene Testing
  • 8.8.1. Table Other Cancer Gene Testing - by Country
  • 8.8.2. Chart - Other Cancer Gene Testing Growth

9. Global Cancer Gene Panels & Profiles Markets - By Type of Application

• 9.1. Clinical Testing
  • 9.1.1. Table Clinical Testing - by Country
  • 9.1.2. Chart - Clinical Testing Growth
• 9.2. Pharmaceutical Testing
  • 9.2.1. Table Pharmaceutical Testing - by Country
  • 9.2.2. Chart - Pharmaceutical Testing Growth
• 9.3. Research Testing
  • 9.3.1. Table Research Testing - by Country
  • 9.3.2. Chart - Research Testing Growth

10. Global Cancer Gene Panels & Profiles Markets - By Tissue Type

• 10.1. Solid Tissue
  • 10.1.1. Table Solid Tissue Testing - by Country
  • 10.1.2. Chart - Solid Tissue Testing Growth
• 10.2. Liquid Tissue Testing
  • 10.2.1. Table Liquid Tissue Testing - by Country
  • 10.2.2. Chart - Liquid Tissue Testing Growth

11. Global Cancer Gene Testing Markets - Germline and Somatic

• 11.1. Global Market Somatic
  • 11.1.1. Table Somatic - by Country
  • 11.1.2. Chart - Somatic Testing Growth
• 11.2. Global Market Germline
  • 11.2.1. Table Germline - by Country
  • 11.2.2. Chart - Germline Testing Growth

12. Potential Market Opportunity Sizes

• 12.1. Potential Cancer Screening by Country: Lung, Breast & Colorectal
• 12.2. Potential Cancer Screening by Country: Prostate, Other Cancer & All Cancer
• 12.3. Potential Market Size - Cancer Diagnosis
• 12.4. Potential Market Size - Therapy Selection

13. Appendices

• 13.1. Growth of Approved IVD Test Menu
• 13.2. Growth of Approved Average IVD Test Fee
• 13.3. The Most Used IVD Assays
• 13.4. The Highest Grossing Assays
• 13.5. Laboratory Fees Schedule